• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 8:00:57 AM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ONCS alert in real time by email
    SC 13G/A 1 oncs-sc13ga_020921.htm AMENDMENT TO FORM SC 13G

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2 )* 

     
    OncoSec Medical Incorporated

    (Name of Issuer) 

     
    Common Stock, par value $0.0001 per share

    (Title of Class of Securities) 

     
    68234L306

    (CUSIP Number) 

     
    December 31,  2020
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    Page 2 of 8

     

    CUSIP No. 68234L306    
           
    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653 

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ 

    (b) x 

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION 

    Delaware, United States of America 

     

    NUMBER OF
    SHARES 

    BENEFICIALLY
    OWNED BY 

    EACH
    REPORTING 

    PERSON
    WITH: 

    5

    SOLE VOTING 

    0 

     
    6

    SHARED VOTING POWER 

    614,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4) (1) 

     
    7

    SOLE DISPOSITIVE POWER 

    0 

     
    8

    SHARED DISPOSITIVE POWER 

    614,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4) (1) 

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

    614,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4) (1) 

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 

    2.2% (See Item 4) (1)(2)

     
    12

    TYPE OF REPORTING PERSON 

    IA, PN 

     
             

     

    (1) As more fully described in Item 4, the Warrants are subject to a 4.99% blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such Warrants and do not give effect to such blockers.

     

    (2)  Based on 27,991,274 shares of Common Stock issued and outstanding as of December 11, 2020, as represented in the Issuer’s 10Q filed with the Securities and Exchange Commission on December 11, 2020.

     

     

     

     

    Page 3 of 8

     

    CUSIP No . 68234L306    
           
    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2105101 

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ 

    (b) x 

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION 

    Delaware, United States of America 

     

    NUMBER OF
    SHARES 

    BENEFICIALLY
    OWNED BY 

    EACH
    REPORTING 

    PERSON
    WITH: 

    5

    SOLE VOTING 

    0 

     
    6

    SHARED VOTING POWER 

    614,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4) (1) 

     
    7

    SOLE DISPOSITIVE POWER 

    0 

     
    8

    SHARED DISPOSITIVE POWER 

    614,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4) (1) 

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

    614,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4) (1) 

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 

    2.2% (See Item 4) (1)(2)

     
    12

    TYPE OF REPORTING PERSON 

    PN 

     
             

     

    (1) As more fully described in Item 4, the Warrants are subject to a 4.99% blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such Warrants and do not give effect to such blockers.

     

    (2) Based on 27,991,274 shares of Common Stock issued and outstanding as of December 11, 2020, as represented in the Issuer’s 10Q filed with the Securities and Exchange Commission on December 11, 2020.

     

     

     

     

    Page 4 of 8

     

    CUSIP No . 68234L306    

             
    1

    NAME OF REPORTING PERSONS 

    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2086430 

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ 

    (b) x 

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION 

    Delaware, United States of America 

     

    NUMBER OF
    SHARES 

    BENEFICIALLY
    OWNED BY 

    EACH
    REPORTING 

    PERSON
    WITH: 

    5

    SOLE VOTING 

    0 

     
    6

    SHARED VOTING POWER 

    614,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4) (1) 

     
    7

    SOLE DISPOSITIVE POWER 

    0 

     
    8

    SHARED DISPOSITIVE POWER 

    614,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4) (1) 

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

    614,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4) (1) 

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 

    2.2% (See Item 4) (1)(2)

     
    12

    TYPE OF REPORTING PERSON 

    OO

     

     

     

     

    (1) As more fully described in Item 4, the Warrants are subject to a 4.99% blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such Warrants and do not give effect to such blockers.

     

    (2) Based on 27,991,274 shares of Common Stock issued and outstanding as of December 11, 2020, as represented in the Issuer’s 10Q filed with the Securities and Exchange Commission on December 11, 2020.

     

     

     

     

    Page 5 of 8

      

    CUSIP No. 68234L306  
         
    Item 1(a).   Name of Issuer: OncoSec Medical Incorporated (the “Issuer”)
         
    Item 1(b).  

    Address of Issuer’s Principal Executive Offices:

    24 North Main Street

    Pennington, NJ 08534-2218 

         
    Item 2(a).  

    Name of Person Filing:

     

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP, Altium Capital Management, LP, and Altium Growth GP, LLC. Altium Growth Fund, LP is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, Altium Growth Fund, LP. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, Altium Growth Fund, LP.

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer. 

         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
        The address of the principal business office of each of the reporting persons is 152 West 57 Street, FL 20, New York, NY 10019
         
    Item 2(c).   Citizenship:
        See Item 4 on the cover page(s) hereto.
         
    Item 2(d).   Title of Class of Securities:
        Common Stock, par value $0.0001 per share (“Common Stock”)
         
    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
           

      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

     

     

     

     

    Page 6 of 8

     

    CUSIP No . 68234L306    

     

      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 27,991,274 shares of Common Stock issued and outstanding as of December 11, 2020, as represented in the Issuer’s 10Q filed with the Securities and Exchange Commission on December 11, 2020, and assumes the exercise of the Issuer’s reported warrants (the “Warrants”) and, subject to the Blockers (as defined below).

     

    Pursuant to the terms of the Warrants, the Reporting Persons cannot exercise the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock (the “Blocker”), and the percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blocker.

     


     

     


    Page 7 of 8

     

    CUSIP No . 68234L306    

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: February 11, 2021  
           
      Altium Capital Management, LP  
           
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: CEO  
           
      Altium Growth Fund, LP  
           
      By: Altium Growth GP, LLC  
      Its: General Partner  
           
      Signature: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member of Altium Growth GP, LLC  
           
      Altium Growth GP, LLC  
           
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member  

     

     

     

     

    Page 8 of 8

     

    EXHIBIT INDEX

     

    EXHIBIT 1:Joint Acquisition Statement Pursuant to Section 240.13d-1(k)
      
     Members of Group

     

     

    Get the next $ONCS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONCS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Delaversano Robert J sold $55 worth of shares (40 units at $1.37), decreasing direct ownership by 4% to 1,008 units (withholding obligation)

    4 - ONCOSEC MEDICAL Inc (0001444307) (Issuer)

    2/9/23 8:11:50 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4: Delaversano Robert J sold $105 worth of shares (283 units at $0.37), decreasing direct ownership by 1% to 22,975 units (tax withholding)

    4 - ONCOSEC MEDICAL Inc (0001444307) (Issuer)

    11/4/22 8:21:02 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Foster Spahr Stephany

    4 - ONCOSEC MEDICAL Inc (0001444307) (Issuer)

    10/12/22 3:49:42 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ONCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    EWING, N.J. and SAN DIEGO, May 18, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced the closing of its previously announced registered direct offering of 1,408,384 shares of its common stock, at a purchase price of $0.945 per share, priced at-the-market under Nasdaq rules. The Company also issued in a concurrent private placement unregistered warrants to purchase up to an aggregate of 1,408,384 shares of common stock. The warrants have an exercise price of $0.82 per sh

    5/18/23 4:30:00 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    EWING, N.J. and SAN DIEGO, May 16, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced that it has entered into a definitive agreement for the purchase and sale of  an aggregate of 1,408,384 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $0.945 per share (or common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. The Company has also agreed to issue in a concurrent

    5/16/23 1:29:00 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program

    EWING, N.J. and SAN DIEGO, May 16, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced a Type C meeting held with the US Food and Drug Administration (FDA) on May 15, 2023. The purpose of the meeting was to discuss the trial design for a planned randomized, open-label Phase 2 clinical trial in patients with high-risk, resectable melanoma to evaluate the neoadjuvant treatment combination of the Company's tavokinogene telseplasmid, a plasmid encoding human interleukin 12 (IL-12

    5/16/23 8:00:00 AM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ONCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on OncoSec Medical with a new price target

    BTIG Research initiated coverage of OncoSec Medical with a rating of Buy and set a new price target of $10.00

    3/15/21 8:10:02 AM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    BTIG Research initiated coverage on OncoSec Medical with a new price target

    BTIG Research initiated coverage of OncoSec Medical with a rating of Buy and set a new price target of $10.00

    3/8/21 6:47:53 AM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ONCS
    SEC Filings

    View All

    SEC Form 25-NSE filed by OncoSec Medical Incorporated

    25-NSE - ONCOSEC MEDICAL Inc (0001444307) (Subject)

    7/10/23 6:08:05 AM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    OncoSec Medical Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - ONCOSEC MEDICAL Inc (0001444307) (Filer)

    6/22/23 8:30:17 AM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    OncoSec Medical Incorporated filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update

    8-K - ONCOSEC MEDICAL Inc (0001444307) (Filer)

    6/14/23 5:20:09 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ONCS
    Financials

    Live finance-specific insights

    View All

    OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study

    PENNINGTON, N.J. and SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:00 AM ET featuring key opinion leaders (KOLs) Matteo Carlino, MD, from Westmead and Blacktown Hospitals, Adil Daud, MD, from University of California San Francisco, Pablo Fernandez Peñas MD, PhD, FACD, from The University of Sydney, and Montaser Shaheen, MD, from the University of Arizona Cancer Center. The KOLs will discuss the clinical relevance of the updated KEYNOTE-695 data being presented in a poster at the SITC 2021 Annual Meeting. Specifically, the KEYNOTE-695 clinical trial enrolled meta

    11/2/21 8:00:00 AM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ONCS
    Leadership Updates

    Live Leadership Updates

    View All

    OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer

    PENNINGTON, N.J. and SAN DIEGO, April 29, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, today announced the appointment of Robert H. Arch, Ph.D., as President and Chief Executive Officer. Dr. Arch was previously Head of Research at Elpiscience Biopharma, Ltd. from October 2019 to June 2021, and Head of the Liver Disease Department at China Novartis Institutes for BioMedical Research from February 2017 to October 2019. Robert's leadership roles have been focused on shaping strong teams and b

    4/29/22 8:00:00 AM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    OncoSec Announces Appointment of George Chi as Chief Financial Officer

    PENNINGTON, N.J. and SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, today announced the appointment of George Chi as Chief Financial Officer. Mr. Chi joins the Company from THPlasma, where he served as Chief Executive Officer since July 2020 and helped found the company's plasma collection business and establish regular commercial sales. Prior to joining THPlasma, Mr. Chi served as Chief Financial Officer of CASI Pharmaceuticals, Inc. ("CASI"), a biopharmaceutical company

    2/22/22 5:59:00 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer

    PENNINGTON, N.J. and SAN DIEGO, June 24, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Daniel O'Connor has resigned and that Brian Leuthner, formerly Chief Operating Officer, has been appointed Interim Chief Executive Officer, effective June 25, 2021.  Mr. O' Connor is also stepping down from his seat on the Board of Directors.   "Under Dan's leadership over the past four years, OncoSec has transformed itself into the leading intra-tumoral cancer immunotherapy Company," said Margaret Dalesandro, Ph.D., Chair of the Board of Directors at OncoSec.  "Dan operationally drove several value-creating clinical programs with the Comp

    6/24/21 4:30:00 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ONCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by OncoSec Medical Incorporated (Amendment)

    SC 13G/A - ONCOSEC MEDICAL Inc (0001444307) (Subject)

    2/13/24 2:30:19 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by OncoSec Medical Incorporated

    SC 13G - ONCOSEC MEDICAL Inc (0001444307) (Subject)

    5/25/23 4:13:04 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by OncoSec Medical Incorporated

    SC 13G - ONCOSEC MEDICAL Inc (0001444307) (Subject)

    5/19/23 2:57:56 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care